Sixteen patients starting endocrine treatment for de novo or progressive breast cancer bone metastases were prospectively recruited to undergo [<sup>18</sup>F]fluoride and [<sup>18</sup>F]FDG PET/CT scans before and 8 weeks after treatment.
False-positive bone lesions mimicking bone metastases (bone pseudometastasis) on F-FDG PET/CT have often been reported in patients with esophageal cancer.
The sensitivity of bone marrow involvement in bone metastases positive patients on <sup>18</sup>F-FDG PET/CT was 75% (3/4), and the specificity was 100% (22/22).
Our findings suggest that FDG-PET evaluation in metastatic bone lesions could be useful to predict initial pain and subsequent clinical outcomes of local bone status in initially diagnosed lung cancer patients with bone metastasis.
The sensitivity, specificity, accuracy, and positive and negative predictive values of <sup>18</sup>F-FDG PET/CT for detecting chest and bone metastases were comparable to those of conventional imaging (<i>p</i> > .1).
Diffuse hepatic epithelioid hemangioendothelioma with multiple splenic metastasis and delayed multifocal bone metastasis after liver transplantation on FDG PET/CT images: A case report.
99mTc-MDP-BS, 18F-FDG-PET/CT and 18F-FCH-PET/CT occurred as comparable imaging methods in bone metastases detection in the prostate cancer patients and provide complementary clinical conclusions.
The specificity, overall accuracy, and PPV of whole-body DWIBS are significantly lower than those of <sup>18</sup>F-FDG PET/CT because of a high incidence of false-positive findings particularly for detecting bone metastasis, whereas whole-body DWIBS shows a similar level of sensitivities for detecting lymph node and bone metastases to those of <sup>18</sup>F-FDG PET/CT.
In prostate and breast cancer, WB-MRI-DWI is useful in assessing the response of bone lesions to therapy and to detecting early non-responders, while in lung cancer the method shows a similar sensitivity to 18F-FDG PET/CT in the detection of bone metastases.
The aim of this study was to evaluate the safety and efficacy of <sup>18</sup>F-FDG PET/CT in guiding biopsy of bone metastases in patients with advanced lung cancer.
Interestingly, 18F-FDG-PET/CT showed that early eradication of individual BM metastasis by systemic treatment precluded development of bone metastasis.
The purpose of our case report is to emphasize the role of FDG PET/CT in the assessment of tumor recurrence and extracranial bone metastases from anaplastic astrocytoma.
<sup>18</sup>FDG PET/PET-CT is superior to BS for diagnosing bone metastases in nasopharyngeal cancer patients.<sup>18</sup>FDG PET/PET-CT may enhance the diagnosis of bone metastases and provide more accurate information for the optimal management of nasopharyngeal cancer.